Supplemental Material

Table S1. Assessment and follow-up schedule

Time point	Enrollment and Treatment		Follow-up				
	Pre-procedural screening	During the procedure	3 days or discharge	30 days	6 months	1 year	3 years
Window phase	-14 to 0 day	0 day	whichever comes first	±3 days	±14 days	±1 month	±3 months
Informed consent	X						
Inclusion/exclusion criteria	X	X					
Past history/demographic data	X						
Vital signs	X		X				
Blood routine	X		X				
Blood biochemistry	X		X				
Coagulation function	X		X				
Clopidogrel resistance test*	X						
ECG	X						
Chest X-ray	X						
CT+CTA or MRI+MRA†	X						
DSA		X			X		X
NIHSS score	X		X				
mRS score	X		X	X	X	X	X
Use of endovascular devices		X					
Concomitant medication	X	X	X	X	X	X	X
AE/SAE		X	X	X	X	X	X
Defects of study devices		X					

*It is recommended to perform thromboelastography and/or CYP2C19 genotype test to detect the presence of clopidogrel resistance, and clopidogrel is shifted to ticagrelor in patients with clopidogrel resistance.
†It is recommended to perform CTP or PWI examination to confirm the presence of hypoperfusion in the territory distal to the target lesion.
Abbreviations: AE, adverse event; CTA, CT angiography; CTP, CT perfusion; DSA, digital subtraction angiography; ECG, electrocardiogram; MRA, MR angiography; mRS, modified Rankin Scale; NIHSS, National Institutes of Health Stroke Scale; PWI, perfusion weighted imaging; SAE, serious adverse event